Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries; The New York Times, October 2, 2024

Stephanie Nolen , The New York Times; Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries

"The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North Africa to make and sell at a lower price its groundbreaking drug lenacapavir, a twice-yearly injection that provides near-total protection from infection with H.I.V.

Those companies will be permitted to sell the drug in 120 countries, including all the countries with the highest rates of H.I.V., which are in sub-Saharan Africa. Gilead will not charge the generic drugmakers for the licenses.

Gilead says the deal, made just weeks after clinical trial results showed how well the drug works, will provide rapid and broad access to a medication that has the potential to end the decades-long H.I.V. pandemic.

But the deal leaves out most middle- and high-income countries — including Brazil, Colombia, Mexico, China and Russia — that together account for about 20 percent of new H.I.V. infections. Gilead will sell its version of the drug in those countries at higher prices. The omission reflects a widening gulf in health care access that is increasingly isolating the people in the middle."

Coronavirus: The global race to patent a remedy; The Mercury News, February 13, 2020

Lisa M. Krieger, The Mercury News; Coronavirus: The global race to patent a remedy

"As a lethal coronavirus triggers a humanitarian crisis in the world’s most populous nation, who owns the rights to a potential cure?

The Bay Area’s pharmaceutical powerhouse Gilead Sciences is first in line for a Chinese patent for its drug called Remdesivir, which shows promise against the broad family of coronaviruses.

But now a team of Chinese scientists say they’ve improved and targeted its use — and, in a startling move, have also filed for a patent...

“Each side wants to be the entity that came up with the treatment for coronavirus,” said Jacob Sherkow, professor of law at the Innovation Center for Law and Technology at New York Law School. “This is not a knockoff of a Louis Vuitton handbag,”...

Patent protection — and market exclusivity — is the lifeblood of drug companies such as Gilead, creating the incentive to find, test and market a medicine."